Supplemental file

Figure S1: NTproBNP levels during VRD therapy at baseline, 3, 6 & 12 months



Figure S2: Comparison of overall survival between VDR and VCD/CyBorD treated patients



Supplemental Table S1: published results of VCD/CyBorD in previously untreated patients with AL amyloidosis

	ORR	VGPR+CR	CR
Kastritis[1] (N=42)	78%	35%	
Palladini [2](N=230)	62%	42%	23%
Venner [3](N=69)	71%	NR	40.5%
Jaccard [4](N=60)	68%	42%	17%
Mikhael[5] (N=17)	94%	NR	71%

1. Kastritis E, Gavriatopoulou M, Roussou M, et al. Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib. Blood Cancer J. 2017 Jun 16;7(6):e570. doi: bcj201747 [pii]
10.1038/bcj.2017.47. PubMed PMID: 28622303; eng.
2. Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015 May 18. doi: blood-2015-01-620302 [pii]
10.1182/blood-2015-01-620302. PubMed PMID: 25987656; Eng.
3. Venner CP, Gillmore JD, Sachchithanantham S, et al. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia. 2014 Jul 16. doi: leu2014218 [pii]
10.1038/leu.2014.218. PubMed PMID: 25027514; Eng.
4. Jaccard A, Comenzo RL, Hari P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica. 2014 Sep;99(9):1479-85. doi: haematol.2014.104109 [pii]
10.3324/haematol.2014.104109. PubMed PMID: 24859879; eng.
5. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012 May 10;119(19):4391-4. doi: blood-2011-11-390930 [pii]
10.1182/blood-2011-11-390930. PubMed PMID: 22331188; PubMed Central PMCID: PMC3557400. eng.